Mental disorders are no predictors to determine the duration of cannabis-based treatment for chronic pain.
bio-psycho-social model
cannabis
cannabis-based medicine
chronic pain
depression
mental disorders
pain disorder
treatment
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2022
2022
Historique:
received:
31
08
2022
accepted:
28
11
2022
entrez:
23
1
2023
pubmed:
24
1
2023
medline:
24
1
2023
Statut:
epublish
Résumé
Chronic pain (CP), a complex biopsychosocial disorder with a global prevalence of up to 33%, can be treated by following multidisciplinary approaches that may include cannabis-based medicine (CBM). However, because CBM continues to be a new treatment, questions remain regarding the ideal duration for CBM and its psychosocial determinants, including mental comorbidities. In a retrospective cross-sectional study involving 46 patients with CP (ICD-10 code F45.4-), three validated instruments-the German Pain Questionnaire, the Depression Anxiety Stress Scale (DASS), and the Marburg Questionnaire of Habitual WellBeing-were used to identify pain-specific psychosocial determinants and mental disorders. Descriptive analyses, a group differences analysis, and a logistic regression analysis were performed using SPSS. The patients most frequently reported low back pain as the primary location of their CP, and in attributing the condition to tissue damage, most had largely adopted a somatic orientation in conceptualizing their illness. Most had experienced CP for more than 5 years ( We found no evidence indicating that the benefits of short-term vs. long-term cannabis-based treatment can be predicted by mental comorbidities or psychosocial factors. However, because CBM may be included in approaches to treat CP, questions about the ideal duration of such treatment remain to be answered.
Sections du résumé
Background
UNASSIGNED
Chronic pain (CP), a complex biopsychosocial disorder with a global prevalence of up to 33%, can be treated by following multidisciplinary approaches that may include cannabis-based medicine (CBM). However, because CBM continues to be a new treatment, questions remain regarding the ideal duration for CBM and its psychosocial determinants, including mental comorbidities.
Methods
UNASSIGNED
In a retrospective cross-sectional study involving 46 patients with CP (ICD-10 code F45.4-), three validated instruments-the German Pain Questionnaire, the Depression Anxiety Stress Scale (DASS), and the Marburg Questionnaire of Habitual WellBeing-were used to identify pain-specific psychosocial determinants and mental disorders. Descriptive analyses, a group differences analysis, and a logistic regression analysis were performed using SPSS.
Results
UNASSIGNED
The patients most frequently reported low back pain as the primary location of their CP, and in attributing the condition to tissue damage, most had largely adopted a somatic orientation in conceptualizing their illness. Most had experienced CP for more than 5 years (
Conclusion
UNASSIGNED
We found no evidence indicating that the benefits of short-term vs. long-term cannabis-based treatment can be predicted by mental comorbidities or psychosocial factors. However, because CBM may be included in approaches to treat CP, questions about the ideal duration of such treatment remain to be answered.
Identifiants
pubmed: 36684012
doi: 10.3389/fpsyt.2022.1033020
pmc: PMC9853059
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1033020Informations de copyright
Copyright © 2023 Rometsch, Ott, Festl-Wietek, Jurjut, Schlisio, Zipfel, Stengel and Herrmann-Werner.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Clin J Pain. 2002 Nov-Dec;18(6):355-65
pubmed: 12441829
Rev Saude Publica. 2015;49:
pubmed: 26487293
BMC Cancer. 2020 May 3;20(1):373
pubmed: 32362277
Rheumatol Int. 2017 Jan;37(1):29-42
pubmed: 27107994
Harv Rev Psychiatry. 2018 Nov/Dec;26(6):352-363
pubmed: 30407234
Eur Arch Psychiatry Clin Neurosci. 2019 Feb;269(1):87-105
pubmed: 30706168
Pain. 2021 Jul 1;162(Suppl 1):S45-S66
pubmed: 32804836
Pain. 2008 Jan;134(1-2):69-79
pubmed: 17504729
Lancet. 2015 Apr 27;385 Suppl 2:S10
pubmed: 26313056
Annu Rev Clin Psychol. 2014;10:339-67
pubmed: 24387234
Soc Sci Med. 2019 Jul;233:181-192
pubmed: 31207470
Lancet. 2015 Aug 22;386(9995):743-800
pubmed: 26063472
Pain. 1992 Aug;50(2):133-149
pubmed: 1408309
Lancet Psychiatry. 2022 Sep;9(9):736-750
pubmed: 35901795
Trans Am Clin Climatol Assoc. 2015;126:167-83
pubmed: 26330672
Eur J Pain. 2010 Apr;14(4):380-6
pubmed: 19726210
Clin J Pain. 2001 Dec;17(4 Suppl):S39-45
pubmed: 11783830
Anesthesiology. 2018 Aug;129(2):343-366
pubmed: 29462012
Schmerz. 2009 Apr;23(2):112-20
pubmed: 19156448
Curr Psychiatry Rep. 2018 Mar 5;20(2):12
pubmed: 29504088
J Pain. 2008 Mar;9(3):254-64
pubmed: 18088560
Neuropsychiatr Dis Treat. 2016 Oct 31;12:2807-2818
pubmed: 27826193
Subst Abuse Treat Prev Policy. 2017 Aug 15;12(1):36
pubmed: 28810899
Eur J Pain Suppl. 2011 Nov 11;5(2):365-372
pubmed: 22102847
Pain. 2018 Sep;159 Suppl 1:S85-S90
pubmed: 30113952
Clin Ter. 2017 May-Jun;169(3):e102-e107
pubmed: 29938740
JAMA. 2018 Dec 18;320(23):2448-2460
pubmed: 30561481
Clin Psychol Rev. 2017 Feb;51:15-29
pubmed: 27816801
Lancet. 1999 Oct 9;354(9186):1248-52
pubmed: 10520633
Eur J Pain. 2021 Feb;25(2):359-374
pubmed: 33065768
J Physiother. 2010;56(3):204
pubmed: 20795931
Pain Physician. 2017 Sep;20(6):E755-E796
pubmed: 28934780
Lancet Public Health. 2018 Jul;3(7):e341-e350
pubmed: 29976328
J Spinal Cord Med. 2022 Sep;45(5):656-667
pubmed: 33465022
Spine J. 2008 Jan-Feb;8(1):8-20
pubmed: 18164449
Neuroimmunomodulation. 1997 May-Jun;4(3):134-53
pubmed: 9500148
Lancet Psychiatry. 2019 Dec;6(12):995-1010
pubmed: 31672337
J Neuroendocrinol. 2001 Dec;13(12):1009-23
pubmed: 11722697
Cannabis Cannabinoid Res. 2021 Dec;6(6):474-487
pubmed: 34664988
Ann Intern Med. 2017 Sep 05;167(5):319-331
pubmed: 28806817
Pain. 2018 Oct;159(10):1932-1954
pubmed: 29847469
Eur J Pain. 2018 Oct;22(9):1547-1564
pubmed: 30074291
Cochrane Database Syst Rev. 2017 Aug 05;8:CD012535
pubmed: 28779487
PM R. 2020 Apr;12(4):410-419
pubmed: 31437355
Curr Psychiatry Rep. 2008 Aug;10(4):318-22
pubmed: 18627670
Qual Life Res. 2009 Oct;18(8):971-80
pubmed: 19688608
MMWR Morb Mortal Wkly Rep. 2018 Sep 14;67(36):1001-1006
pubmed: 30212442
J Pain. 2013 Feb;14(2):136-48
pubmed: 23237736
Mayo Clin Proc. 2016 Jul;91(7):955-70
pubmed: 27344405
Can J Physiol Pharmacol. 1991 May;69(5):662-71
pubmed: 1863918
Schmerz. 2017 Dec;31(6):555-558
pubmed: 29143118
Occup Med (Lond). 2001 Mar;51(2):124-35
pubmed: 11307688
BMJ. 2021 Sep 8;374:n1034
pubmed: 34497047
Rev Rhum Engl Ed. 1997 Mar;64(3):189-94
pubmed: 9090769
Schmerz. 2015 Dec;29(6):649-57
pubmed: 26205682
Cochrane Database Syst Rev. 2018 Mar 07;3:CD012182
pubmed: 29513392